ScreenDx
Overview
ScreenDx by Imvaria is an FDA-cleared, software-only clinical AI tool designed to automatically analyze chest computed tomography (CT) imaging data for findings suggestive of interstitial lung disease (ILD). It operates as an automated, background-only screening algorithm that requires no manual operation by technologists or expert users.
The tool is built for clinicians and healthcare organizations, particularly pulmonologists and radiologists, to assist in identifying potential ILD cases during routine imaging assessments. By integrating directly into existing imaging workflows, ScreenDx functions as an incidental screening and triage system. It automatically parses CT scans to flag findings compatible with ILD, helping to streamline patient referral pathways to qualified specialists for timely evaluation and treatment.
- Automated Background Processing: Runs silently in the background of standard imaging workflows without requiring manual intervention.
- Pattern Recognition: Utilizes machine learning to detect subtle interstitial lung findings amidst other common pulmonary conditions like COPD, emphysema, and cancer.
- Referral Optimization: Provides adjunctive data to support earlier clinical identification and accelerate the referral pipeline to specialized pulmonary care.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered analysis of CT scans for interstitial lung findings
- Early identification of potential Interstitial Lung Disease (ILD) cases
- Enhances referral pathways to specialists
- Supplements standard-of-care workflows
- Provides qualitative output based on pattern recognition
- Seamless integration into existing clinical workflows
- Automated operation, no expert user needed
- Validated against various disease states (e.g., COVID, cancer, COPD/emphysema)
- Software-only medical device
- Accepts DICOM-compliant lung CT scan input
Use Cases
- Screening for Interstitial Lung Disease (ILD)
- Assisting clinicians in diverse settings (emergency rooms, lung cancer screenings, specialized clinics)
- Reducing diagnostic delays for ILD
- Guiding timely referrals to pulmonologists and other qualified clinicians
- Complementing traditional diagnostic tools for lung disease assessment
- Improving clinical decision-making for patients with suspected lung diseases
What Physicians Need to Know
ScreenDx is an AI-powered tool designed to assist in the early identification of potential Interstitial Lung Disease (ILD) cases from CT scans. It acts as a supplementary tool to enhance referral pathways and should be used in conjunction with a patient's clinical history, symptoms, and other diagnostic tests, as well as the clinician's professional judgment. ScreenDx does not replace standard diagnostic methods for lung fibrosis and is not intended to rule out or rule in lung fibrosis. The tool aims to streamline the diagnostic pathway, especially for serious diseases like ILD, by identifying patients efficiently, regardless of whether they are first seen in emergency, lung cancer screening, or specialty clinical settings.
ScreenDx is designed for seamless integration into existing clinical workflows. It utilizes an Image Receiver API for acquiring DICOM-compliant lung CT scans and an Output API for transmitting results to hospital or clinic notification software (e.g., EHR, messaging systems). IMVARIA has partnered with Viz.ai to leverage ScreenDx technology to enhance Viz.ai's suite of intelligent solutions for identifying patients who may benefit from specialized evaluation and therapy for pulmonary conditions. IMVARIA's AI Lab also offers other FDA-cleared AI solutions, such as InVision Precision Cardiac Amyloid (PCA) for cardiac amyloidosis, on a referral basis.
Details
| Category | Clinical Decision Support & Reference, Radiology & Imaging AI |
| Pricing | Unknown |
| Deployment | Cloud-based digital lab |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Pulmonology, Radiology |
What the Web Says
ScreenDx by IMVARIA is an FDA-cleared AI-powered tool designed to analyze CT scans for findings compatible with interstitial lung disease (ILD). It aims to assist clinicians in early identification and referral of patients, thereby reducing diagnostic delays for this serious condition. ScreenDx operates as a background technology, automatically sifting through CT scans without requiring expert user operation.
Overall: PositiveStrengths
- FDA-cleared technology for assessing interstitial lung findings compatible with ILD.
- Aids in early identification and referral of patients with potential ILD, reducing diagnostic delays.
- Automated and operates in the background, requiring no technologist or expert user.
- Demonstrated high performance across multi-site datasets and is generalizable across different CT manufacturers and slice thicknesses.
- Supplements existing clinical workflows and does not replace standard diagnostic methods.
- Validated to identify ILD among a wide range of scans, including those with COVID, cancer, and COPD/emphysema.
Limitations
- Does not replace current standard of care methods for diagnosis of lung fibrosis.
- Results are not intended to rule-out or rule-in lung fibrosis.
- Intended to be used only by clinicians qualified in the care of lung disease, in conjunction with other clinical information and professional judgment.
- Limited independent user reviews from physicians, healthcare IT, Reddit, G2, or Capterra were found in the search results.
Based on reviews from: imvaria.com, businesswire.com, nih.gov, medtechinnovator.org, xtalks.com, respiratory-therapy.com, biospace.com, g2.com, mtec-sc.org, medpath.com
Last updated: 2026-10-30
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate ScreenDx
Press & Coverage
Frequently Asked Questions
Investors who backed ScreenDx
Funded through the company that built this tool.
